<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844322</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2015005-EC-2</org_study_id>
    <nct_id>NCT02844322</nct_id>
  </id_info>
  <brief_title>The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia</brief_title>
  <acronym>BDH-WM01</acronym>
  <official_title>The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of cyclophosphamide plus dexamethasone
      combined with rituximab or bortezomib regimens in newly diagnosed Waldenström
      macroglobulinemia patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Newly diagnosed WM patients will be randomly assigned to BCD or RCD group for introduction
      chemotherapy. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better
      response achieves, addition 3 cycles will be given. If not, patients will be crossed to
      control group for another 3 cycles. If a PR or better response comes out, addition 3 cycles
      will be given, otherwise, the patients will quit this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progress-free survival</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Waldenström Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive bortezomib+ cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to RCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive rituximab+cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to BCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia</description>
    <arm_group_label>Bortezomib</arm_group_label>
    <other_name>velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia</description>
    <arm_group_label>rituximab</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged &gt;=18 years

          2. diagnosed with LPL/WM

          3. untreated or mild treated without standard regimens,especially untreated with
             rituximab and/or bortezomib

          4. symptom patients

          5. with life-expectancy more than 3 months.

        Exclusion Criteria:

          1. diagnosed with other malignancies outside B-NHL within one year(including active
             center neural system lymphoma)

          2. transformed lymphoma

          3. liver or renal function lesion unrelated to lymphoma

          4. serious complications such as uncontrolled diabetes,gastric ulcer or other serious
             angiocardiopathy determined by the physician

          5. HIV positive or active HBV infection or other uncontrolled systematic infection

          6. clinical central nervous dysfunction

          7. serious surgery within 30 days

          8. pregnancy or baby nursing period or un-contracepted child-bearing period woman; 9.
             allergy to the trail drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuhua Yi, Doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuhua Yi, Doc</last_name>
    <phone>86-22-23909106</phone>
    <email>yishuhua@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lugui Qiu, Doc</last_name>
    <phone>86-22-23909172</phone>
    <email>qiulg@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shuhua Yi</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuhua Yi, Doc</last_name>
      <phone>86-22-23909106</phone>
      <email>yishuhua@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lugui Qiu, Doc</last_name>
      <phone>86-22-23909172</phone>
      <email>qiulg@ihcams.ac.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Yi Shuhua</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>we will make the data publicly available according to the local law</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

